Advertisement

Read Annals this month

| | November 10, 2025

Read Annals this month

The falling leaves and cooler temperatures tell us it is November – a great time to catch up on our scientific reading. This month Annals of Allergy, Asthma & Immunology provides an update on atopic dermatitis. With review articles from the leading experts in the field, you will get the knowledge needed to provide outstanding up-to-date care for your patients.

Our CME review article this month explores infectious complications of atopic dermatitis. Other reviews in the issue explore the epidemiology and comorbidities of atopic dermatitis, as well as an update on the new treatments (and there are many) for this troubling disease. As a bonus this month, an additional review is provided exploring mast cell conditions and drug allergy.

Original articles this month explore asthma prevalence in Latin America, impact of mepolizumab on quality of life in severe eosinophilic asthma, as well as how well asthma clinical trials do in terms of diversity, equity, and inclusion. Food allergy articles this month include one aligned with our theme, which explores the clinical course of food allergy in children and adolescents with atopic dermatitis who are treated with dupilumab. Other full-length articles this month report outcomes of a 16-year study of food protein-induced enterocolitis syndrome (FPIES), the use of lanadelumab for hereditary angioedema control, and a one-bag protocol for cancer drug hypersensitivity.

Letters this month are equally illuminating, and cover topics including allergic bronchopulmonary aspergillosis, severe asthma outcomes, oral immunotherapy, and penicillin delabeling in patients with syphilis. In addition, this month we have another “10 things…” article, this one focused on chronic rhinosinusitis. This is an article you likely will want to have with you in the clinic when treating your patients.

For a chuckle this month, read the Marginal Zone. You will learn about Desi the Corneodesomosome and LEKTI, also known as Lympho-epithelial Kazal Type Inhibitor, who are neighbors in the stratum granulosum, and LEKTI’s efforts to stop violent Kallikrein from chopping up Desi. It is a struggle and story worthy of a daytime soap opera!

As you enjoy your turkey or other traditional treats to celebrate Thanksgiving, be sure to sit down and read this month’s Annals cover to cover.  Annals’ goal is to provide the most up-to-date information so you can provide the best possible care for your patients. As we ask every month, please email us (annals@ACAAI.org) with comments –especially if articles published in Annals have impacted your practice. Let us know how they have changed the care you provide to your patients.

Mitchell H. Grayson, MD, FACAAI
Editor-in-Chief

Annals Logo
Secret Link

Advertisement